Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
77,036,054
-
Shares change
-
+8,527,394
-
Total reported value, excl. options
-
$657,934,234
-
Value change
-
+$69,958,551
-
Put/Call ratio
-
5.4%
-
Number of buys
-
73
-
Number of sells
-
43
-
Price
-
$8.54
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q2 2023
As of 30 Jun 2023 Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) had 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 77,036,054 shares of stock of the company.
Largest 10 holders included BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., BROWN CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, HHLR ADVISORS, LTD., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, NEW YORK STATE COMMON RETIREMENT FUND, WELLINGTON MANAGEMENT GROUP LLP, and MACQUARIE GROUP LTD.
This table shows 128 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.